What causes pretibial myxedema in patients with Graves' disease or hyperthyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pretibial Myxedema Causes

Pretibial myxedema is caused by autoimmune stimulation in Graves' disease, where thyroid-stimulating hormone receptor antibodies (and possibly IGF-1 receptor antibodies) trigger fibroblast activation and excessive glycosaminoglycan deposition in the dermis.

Primary Autoimmune Mechanism

The underlying cause is an autoimmune process targeting connective tissue:

  • All patients with pretibial myxedema have elevated serum concentrations of thyroid-stimulating hormone receptor antibodies, indicating severe autoimmune activity 1
  • TSH receptors in connective tissue serve as the antigen responsible for the immune process, similar to the mechanism in Graves' ophthalmopathy 1
  • Recent evidence suggests IGF-1 receptor involvement in the pathogenesis, though the exact role remains under investigation 2
  • Both humoral and cellular immune mechanisms stimulate fibroblasts to produce excessive amounts of glycosaminoglycans (acid mucopolysaccharides) 3, 1

Associated Thyroid Conditions

While most commonly linked to Graves' disease, pretibial myxedema can occur in other thyroid states:

  • Graves' disease is responsible for the vast majority of cases, representing a distinctive dermal manifestation alongside ophthalmopathy 4
  • It occasionally occurs in Hashimoto's thyroiditis (chronic autoimmune thyroiditis) 1
  • Pretibial myxedema can present in euthyroid patients with underlying thyroid gland autonomy, even without clinical hyperthyroidism, diffuse goiter, or exophthalmos 5

Localization Factors

The pretibial location is not random but relates to specific mechanical factors:

  • Localization in the pretibial area relates to mechanical factors and dependent position of the lower legs 1
  • Occurrence in areas other than pretibial skin indicates a systemic autoimmune process 1
  • The anterior and lateral surfaces of both tibias are typically affected due to gravitational and lymphatic drainage patterns 2

Clinical Context and Timing

Understanding when pretibial myxedema develops helps clarify its causation:

  • Prolonged and intense autoimmune aggression is necessary for pretibial myxedema manifestation 2
  • Almost invariably, pretibial myxedema follows the onset of ophthalmopathy and develops after diagnosis and treatment of hyperthyroidism 3
  • Pretibial myxedema preceding Graves' ophthalmopathy is rare, though it can be the earliest manifestation leading to diagnosis 3
  • Almost all cases are associated with relatively severe ophthalmopathy, indicating the severity of the underlying autoimmune condition 1

Common Pitfall

A critical diagnostic consideration: In patients with suspect pretibial skin lesions but no obvious hyperthyroidism, a thyrotropin-releasing hormone stimulation test may be required to establish subtle thyroid gland autonomy and diagnose euthyroid pretibial myxedema 5. Missing this can delay diagnosis when typical Graves' disease features are absent.

References

Research

Pretibial myxedema: pathophysiology and treatment options.

American journal of clinical dermatology, 2005

Research

Pretibial myxedema as the initial manifestation of Graves' disease.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Euthyroid pretibial myxedema.

The American journal of medicine, 1987

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.